Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER2 | P43116 | 7/20 | 0.32 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.32 |
| ▸ | ITGAV | P06756 | 2/20 | 0.32 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | USP8 | P40818 | 1/20 | 0.30 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.30 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.30 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL534420 | 0.89 | ADAM17 (0.37) | ADAM17ITGAVSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL3458635 | 0.81 | PTGER2 (0.33) | PTGER2 | |
| SCHEMBL15647720 | 0.81 | PTGER2 (0.43) | PTGER2 | |
| SCHEMBL3458629 | 0.80 | F2 (0.31) | PTGER2ADAM17SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL6516015 | 0.79 | PTGER2 (0.31) | PTGER2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL533748 | 0.78 | SLC1A3 (0.32) | PTGER2ADAM17ITGAVSLC1A3SLC1A2 | |
| SCHEMBL534421 | 0.77 | SLC1A3 (0.31) | ADAM17SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL533794 | 0.72 | PTGER2 (0.49) | PTGER2 | |
| Hydrochloric Acid SCHEMBL533660 | 0.72 | PTGER2 (0.49) | PTGER2 | |
| SCHEMBL11021873 | 0.72 | PTGER2 (0.40) | PTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110054172-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | UBE CORPORATION (JP) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110054172-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | PTGER2, PTGER1, PTGDR2 | PTGER2 1/4885ADAM17 4061/4885ITGAV 1645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.